While not suited for conservative income investors, these two top biotech stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry points.
Thursday's top analyst upgrades and downgrades included Amgen, Biogen, Commscope, Lockheed Martin, Northrop Grumman, ONEOK, Plug Power and Roku.
Tuesday’s top analyst upgrades and downgrades included Amgen, Cirrus Logic, Hain Celestial, Johnson & Johnson, Lam Research, Merck, Spotify Technology and Vertex Pharmaceuticals.
24/7 Wall St. takes a look at Georgia Representative Marjorie Taylor Greene and what stock trades are going on around her.
With the first quarter soon coming to an end, now is the time to move from momentum to strong growth stocks. Goldman Sachs feels these four could offer extra strength in a…
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
The 2021 Dogs of the Dow are now known, and investors who may want to follow this investing strategy have got some thinking to do.
Tuesday's top analyst upgrades and downgrades included Amgen, Amphenol, Continental Resources, EOG Resources, FedEx, IMAX and Splunk.
One popular investment strategy, known as the Dogs of the Dow, has performed better than last year. What's ahead for the dogs in 2021?
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Thursday's top analyst upgrades and downgrades included Amgen, Boeing, eBay, Etsy, Fastly, Fiverr, Ford, General Electric, Gilead Sciences, Pinterest and Six Flags.
Amgen and Gilead released their most recent financial results after the closing bell on Wednesday.
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amazon.com, Amgen, Biogen, Hasbro, Kinder Morgan, SAP, Spotify and Twitter.
